2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2644

The Relationship Between Disease Activity and Cognitive Impairment in Patients with Rheumatoid Arthritis
Abstract Number: 2645

Changes in Clinical Disease Activity Index and Changes in Sleep Among RA Patients Initiating Disease Modifying Antirheumatic Drugs
Abstract Number: 2646

Different Wording of the Patient Global Assessment Scale Leads to Different Rating of Disease Activity
Abstract Number: 2647

Correlations Between Personality Types, Disease Activity and Quality of Life in As and RA Patients
Abstract Number: 2648

Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Abstract Number: 2649

Test-Retest Reliability of the 5-Item Compliance Questionnaire Rheumatology and Factors Influencing Its Assessment of Adherence in Patients with Rheumatoid Arthritis
Abstract Number: 2650

Impact of Patient Education on the Satisfaction of Rheumatoid Arthritis Patient : A Randomized Trial of Nurse-Led Vs. Physician-Led Education
Abstract Number: 2651

Evaluation of the Impact of Disease-Modifying Antirheumatic Drugs on Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice
Abstract Number: 2652

Power Doppler Ultrasound Features in Rheumatoid Arthritis Patients in Clinical Remission: Reclassifying Disease Activity?
Abstract Number: 2653

Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis
Abstract Number: 2654

The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry
Abstract Number: 2655

Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
Abstract Number: 2656

Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Abstract Number: 2657

Influence of Anxiety and Depression on the Swollen to Tender Joint Count Ratio: In Pursuit of a Phenotype of RA Patients with Somatic Complaints in a U.S. Veteran Population
Abstract Number: 2658

Low Disease Activity Is Associated with Higher HDL and a Trend to Lower Insulin Resistance in Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].